Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says
12.01.2026
Jan 12 (Reuters) - Gilead Sciences' new HIV prevention drug has been added to CVS Health's commercial insurance plans, the drugmaker's CEO Daniel O'Day said at a major industry conference that kicked off on Monday in San Francisco. "CVS has confirmed their coverage of Yeztugo as of January 1, putting us at more than 80% (insurer) coverage overall," O'Day said.